-
Medicenna Therapeutics Announces CA$20 Million Investment from RA Capital Management
26 Apr 2024 12:00 GMT
… IL-2, IL-4 and IL-13 Superkines and first-in-class … and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and …
-
Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual Meeting
24 Apr 2024 14:05 GMT
… and uniformly fatal form of brain cancer. Results from the Phase 2b … IL-2, IL-4 and IL-13 Superkines and first-in-class … and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and …
-
Medicenna Presents at National Brain Tumor Society’s Research Round Table
25 Jul 2023 11:26 GMT
… the Brain Cancer Research Roundtable organized by the National Brain Tumor Society … organized by the National Brain Tumor Society (NBTS). The event … 2, IL-4 and IL-13 Superkines and first in … Our focus on defeating brain tumors and improving the quality …
-
Medicenna Presents at National Brain Tumor Society's Research Round Table
25 Jul 2023 11:00 GMT
… the Brain Cancer Research Roundtable organized by the National Brain Tumor Society … organized by the National Brain Tumor Society (NBTS). The event … 2, IL-4 and IL-13 Superkines and first in … Our focus on defeating brain tumors and improving the quality …
-
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
10 Apr 2024 10:30 GMT
… IL-2, IL-4 and IL-13 Superkines and first-in-class … and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and …
-
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
09 Apr 2024 20:30 GMT
… IL-2, IL-4 and IL-13 Superkines and first-in-class … and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and …
-
Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
09 Apr 2024 16:01 GMT
… , prostate, ovarian, breast and brain cancer affecting over two million patients … cleavage and release of the IL-13 tumor-targeting/masking … many aggressive solid tumors. The IL-13 Superkine (MDNA213) is a … -2, IL-4 and IL-13 Superkines and first-in-class …
-
Medicenna Presents Preclinical IL-13 Superkine Data at the AACR Annual Meeting
17 Apr 2023 11:00 GMT
… characterizing the Interleukin 13 (IL-13) Superkines, MDNA132 and … ability of our IL-13 Superkines to preferentially … Characterization of MDNA132, an IL-13 Decoy Receptor Selective Superkine … uniformly fatal form of brain cancer. Bizaxofusp has obtained …
-
Clinical trial approved by FDA for glioblastoma brain cancer
16 Mar 2022 01:45 GMT
… recurrent glioblastoma, a type of brain cancer. The phase I trial is … of the IL-4 and IL-13 cytokine receptor complex. This therapeutic …
-
Medicenna to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
04 Apr 2024 11:00 GMT
… IL-2, IL-4 and IL-13 Superkines and first-in-class … and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and …